Literature DB >> 22252179

Predominance of G to A codon 12 mutation K-ras gene in Dukes' B colorectal cancer.

O Zulhabri1, J Rahman, S Ismail, M R Isa, W N Wan Zurinah.   

Abstract

INTRODUCTION: K-ras gene mutations in codons 12 and 13 are one of the earliest events in colon carcinogenesis.
METHODS: DNA was extracted from 25 mg of tumour tissue (n = 70) that were taken from tumour mass and pairs with normal epithelial tissue distant from the tumour of colorectal cancer patients. Exon 1 and exon 2 of the K-ras gene were amplified. Hotspot mutations were detected using polymerase chain reaction-based single-strand conformation polymorphism method and confirmed by direct DNA sequencing analysis.
RESULTS: Mutations were identified in 14 out of the 70 (20%) colorectal carcinoma tissues. Single-base transition from GGT to GAT (glycine to aspartate) in codon 12 was detected in nine samples, while three samples presented with GGC to GAC transition in codon 13. Patients with large adenoma had a 12-fold higher likelihood of K-ras mutations (odds ratios [OR] 12.31; 95% confidence intervals [CI] 1.81-83.76). Tumours located at the left colon were more likely to present with K-ras mutations (OR 4.54; 95% CI 0.96-21.54).
CONCLUSION: Our study showed a high frequency of G to A transition of codon 12 mutation of the K-ras gene, with significant correlation with tumour size and tumour location.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22252179

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  7 in total

1.  Missense mutations in MLH1, MSH2, KRAS, and APC genes in colorectal cancer patients in Malaysia.

Authors:  Nor Azian Abdul Murad; Zulhabri Othman; Melati Khalid; Zuraini Abdul Razak; Rosniza Hussain; Sukumar Nadesan; Ismail Sagap; Isa Mohamed Rose; Wan Zurinah Wan Ngah; Rahman Jamal
Journal:  Dig Dis Sci       Date:  2012-06-06       Impact factor: 3.199

2.  Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors.

Authors:  Hilmi Kodaz; Ilhan Hacibekiroglu; Bulent Erdogan; Esma Turkmen; Hilmi Tozkir; Dogan Albayrak; Sernaz Uzunoglu; Irfan Cicin
Journal:  Mol Clin Oncol       Date:  2014-10-27

3.  Association between clinicopathological features and survival in patients with primary and paired metastatic colorectal cancer and KRAS mutation.

Authors:  Xue-Lian Pang; Qiao-Xin Li; Zhi-Ping Ma; Yi Shi; Yu-Qing Ma; Xin-Xia Li; Wen-Li Cui; Wei Zhang
Journal:  Onco Targets Ther       Date:  2017-05-19       Impact factor: 4.147

4.  Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants.

Authors:  Arman Ali Ghodsinia; J-Ann Marie T Lego; Reynaldo L Garcia
Journal:  Cells       Date:  2020-04-30       Impact factor: 6.600

Review 5.  Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?

Authors:  Hidayati Husainy Hasbullah; Marahaini Musa
Journal:  Int J Mol Sci       Date:  2021-11-03       Impact factor: 5.923

6.  Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer.

Authors:  Aleksandra Bożyk; Paweł Krawczyk; Katarzyna Reszka; Kinga Krukowska; Agnieszka Kolak; Sławomir Mańdziuk; Kamila Wojas-Krawczyk; Rodryg Ramlau; Janusz Milanowski
Journal:  Arch Med Sci       Date:  2021-03-24       Impact factor: 3.707

7.  Characterization of rare transforming KRAS mutations in sporadic colorectal cancer.

Authors:  Joanna H M Tong; Raymond W M Lung; Frankie M C Sin; Peggy P Y Law; Wei Kang; Anthony W H Chan; Brigette B Y Ma; Tony W C Mak; Simon S M Ng; Ka Fai To
Journal:  Cancer Biol Ther       Date:  2014-03-18       Impact factor: 4.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.